Paper of the Month - February, 2012

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.



READER POLL

L&L poll 2
What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?






Powered by NetPolls

SUBMIT AN ARTICLE